BL-8040 Addition to Consolidation Therapy in AML Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of BL-8040 to the standard consolidation therapy with
cytarabine in the treatment of acute myeloid leukemia (AML) in adults. Half of participants
will receive BL-8040 and cytarabine in combination, while the other half will receive placebo
and cytarabine.